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Summary
The risk of developing autoimmune diseases depends on
both genetic and environmental factors, with epigenetic
mechanisms of regulation potentially translating environ-
mental cues into stable modifications in gene expression.
Such stable memory of a functional state has been de-
ciphered into a number of molecular mechanisms that col-
lectively define the epigenetic status of a cell. In recent
years, it has become increasingly clear that epigenetic
modifications are highly dynamic and are able to adapt to
the changing environment, with important impact on the
onset and development of a number of diseases. Here, we
describe some of the epigenetic mechanisms of regulation
of cellular functional states in T lymphocytes, with a partic-
ular focus on DNA methylation. We will also discuss cur-
rent knowledge on the role of epigenetics in autoimmunity
and consider open questions in the field.
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DNA methylation and
hydroxymethylation dynamics in the
regulation of gene expression
“Epigenetic” classically described inheritable phenotypes
that are not the result of alterations in the DNA sequence
[1, 2]. Here, however, we will utilise a broader interpret-
ation of such a definition to include all mechanisms that
can provide stability to a given phenotype, including those
that can be important to impart short-term memory of an
environmental signal [3, 4]. Mechanisms providing such
cellular memory of gene expression include histone modi-
fications, as well as regulation mediated by microRNAs
(miRNAs) [3], although we will mainly focus on DNA
methylation dynamics and their role in regulating functions
of T lymphocytes during normal immune responses, as
well as in autoimmunity.
DNA methylation
DNA methylation occurs most commonly at the 5’ position
of the cytosine ring in the context of CpG dinucleotides,
and is mediated by DNA methyltransferase enzymes
(DNMT1, DNMT3a, DNMT3b), which show variable af-
finities for unmethylated and hemimethylated DNA. The
importance of proper DNA methylation throughout mam-
malian development is highlighted by the consequences of
germline deletions of DNMTs: Dnmt1 and Dnmt3b dele-
tions in mice are embryonically lethal, and Dnmt3a-null
mice die perinatally [5, 6].
The relevance of these enzymes can also be inferred from
the fact that they are often found mutated in a variety of
Figure 1
DNA methylation and hydroxymethylation. Cytosine
modifications in DNA have functional consequences on gene
expression. (a) Cytosine can be methylated by DNMT enzymes to
give rise to 5mC, which can be oxidised by TET enzymes to 5hmC
and further products (5fC and 5caC). In an active demethylation
pathway, these products of TET enzymatic activity are likely to be
excised and repaired by the thymine-DNA glycosylase enzyme and
base excision repair mechanisms to regenerate the unmodified
cytosine. Methylated DNA can be recognised by MBD proteins that
can recruit histone modifying complexes (HMTs and HDACs). (b)
DNA methylation occurs at regulatory regions (such as promoters),
but also in gene bodies. DNMT enzymes are responsible for 5mC
deposition, often resulting in the transcriptional repression of the
methylated promoter. TET proteins activity can lead to
demethylation with a potential for transcriptional activation.
5caC = 5-carboxylcytosine; 5fC = 5-formylcytosine; 5hmC =
5-hydroxymethylcytosine; 5mC = 5-methylcytosine; BER = base
excision repair; DNMT = DNA methyltransferase; HDAC = histone
deacetylase; HMT = histone methyltransferase; MBD = methyl-
CpG-binding domain protein; TDG = thymine-DNA glycosylase;
TET = ten-eleven translocation
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diseases. For example, DNMT3a is frequently mutated in
a number of haematological malignancies, and upon trans-
plantation of haematopoietic stem cells lacking DNMT3a,
mice develop a spectrum of malignancies similar to those
seen in patients with mutations in this enzyme, supporting
the crucial role of DNA methylation in disease [7, 8].
Mutations in the gene encoding for DNMT3b are instead
found in patients with ICF (immunodeficiency, centromere
instability and facial anomalies), a recessive autosomal
syndrome, and were shown to lead to reduced DNA
methyltransferase activity [9].
Methylated DNA provides a platform for the binding of
several methyl-CpG-binding domain (MBD) proteins,
which can coordinate downstream processes by recruiting
multiprotein complexes containing histone deacetylases
(HDACs) and histone methyltransferases (HMTs), leading
to chromatin modifications and alterations in gene expres-
sion [5, 10]. However, histone tails can also influence re-
cruitment of DNMTs, which was in fact shown to be in-
dependent of pre-existing DNA methylation [11]. Indeed,
methylation at lysine 4 of histone H3 (H3K4) was shown
to inhibit DNMT3a recruitment [12, 13], and H3K36me3
modulated DNMT3b binding and consequent DNA
methylation specifically to transcribed gene bodies [11].
Importantly, accessibility of selected transcription factors is
also influenced by DNA methylation, since the methylation
status of a binding site can define binding affinity and even
specificity for a given transcription factor [14–17].
Despite such prominent progress in the field and decades
of intensive studies, the precise role of DNA methylation
in regulating gene expression is still not completely un-
derstood, and many concepts about DNA methylation have
had to be reconsidered in recent years. DNA methylation
was classically associated with gene silencing, and this
is indeed usually the case at transposable elements and
gene promoters, but methylation downstream of the tran-
scriptional start site (TSS) usually does not block elonga-
tion [18]. Moreover, DNA methylation was not necessarily
considered of general importance, since model organisms
such as Drosophila melanogaster and Caenorhabditis eleg-
ans show very low or essentially no cytosine methylation
[19]. However, while cytosine methylation represents the
dominant DNA modification in humans, very recent work
showed how organisms with virtually no cytosine methyl-
ation show significant levels of other DNA modifications,
such as N6-methyladenine (6mA), further highlighting a
possible widespread regulatory role of DNA methylation
(reviewed in [20]). Finally, DNA methylation was thought
to be substantially irreversible, other than through passive
mechanisms of dilution, but the recent discovery of path-
ways leading to DNA demethylation have led to a revision
of this idea.
An effort to describe the methylome of up to 17 eukaryotic
genomes was able to show that DNA methylation is highly
conserved in eukaryotes, and that is was likely present in a
common ancestor [19, 21, 22]. Interestingly, methylation of
the gene body was a highly conserved feature across gen-
omes, with exons being usually more methylated than in-
trons and with reduced methylation at both the promoter
region and the 3’ end of genes. While gene expression
was mostly inversely correlated with promoter methyla-
tion, gene body methylation showed a parabolic correlation
with expression: modestly expressed genes are more likely
to be methylated, while both high and low expressers are
the least likely to be methylated [19, 21, 22]. This gener-
ally conserved pattern indicates a role of DNA methylation
in regulating multiple steps of transcription, including ini-
tiation, elongation, termination and even splicing [19, 23].
Indeed, genome-wide studies showed that removal of one
DNMT enzyme leads to both hypo- and hypermethylation
at specific loci, underlying the complexity of the regulation
mediated by DNA-modifying enzymes and further high-
lighting the fact that DNA methylation does not always
equate to gene silencing [24, 25].
Overall, these studies clearly challenged the general dogma
that DNA methylation invariably corresponds to transcrip-
tional silencing, and put forward the idea that the final out-
come on transcriptional regulation relates to the context
and spatial distribution of DNA methylation [10]. There-
fore, DNA methylation appears to be intimately associated
with gene transcription.
Reversal of DNA methylation by hydroxylation
Once thought to be a stable chromatin modification, DNA
methylation is now understood to have a much more dy-
namic nature, as its distribution is influenced by DNA de-
methylation processes, which can occur either passively,
by dilution upon DNA replication at each cell division, or
through an active process initiated by ten-eleven transloca-
tion (TET1-3) enzymes [26] (fig. 1). These enzymes are re-
sponsible for the catalytic conversion of 5-methylcytosine
(5mC) to 5-hydroxymethylcytosine (5hmC) and to further
oxidation products, including 5-formylcytosine (5fC) and
5-carboxylcytosine (5caC) [27, 28]. Similarly to DNMT
enzymes, TET proteins are frequently found mutated in a
number of diseases. Specifically, mutations in the TET2
gene are common in many haematological disorders, and
mice lacking TET2 show expansion of the pool of haema-
topoietic stem cells, with a bias towards myelopoiesis,
which in some cases can turn to myeloproliferative disor-
der [29–33].
Although the biological significance of such oxidation de-
rivatives of 5mC remains to be fully elucidated, several
lines of evidence have determined their importance in tran-
scriptional regulation. Indeed, they are likely to be interme-
diates in processes of DNA demethylation and they modi-
fy the binding patterns of several chromatin regulators and
transcription factors, thereby influencing transcription. A
recent work undertook the challenge of investigating the
identity of a large number of 5mC and 5hmC-interacting
proteins in the mouse, revealing that each cytosine modi-
fication is able to recruit a distinct set of proteins with little
overlap, and also that a large number of proteins prefer-
entially interact with unmethylated cytosines [15]. These
findings further indicate that the role of DNA methylation
is integral to regulation (both positive and negative) of tran-
scription. In general, because many of the methods used to
study DNA methylation in the past could not distinguish
between 5mC and 5hmC [34], it will be interesting to see
how many of the functions attributed in the past to 5mC are
actually dependent (or not) on the presence of 5hmC in the
genome.
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Epigenetic regulation of T cell
functions
T lymphocytes are central to the orchestration of immune
responses to invading pathogens, but their activity has to
be carefully balanced and controlled to avoid tissue dam-
age and pathology. Following antigenic stimulation, naïve
T cells proliferate and differentiate into a number of effect-
or and memory subsets, each characterised by the ability to
produce specific signature cytokines. For example, CD4+
T helper (Th) cells differentiation to the Th1 subset is char-
acterised by the production of high levels of interferon-
gamma (IFNγ). Th2 cells instead mainly produce interleuk-
in (IL)-4 and IL-13, while Th17 cells are characterised by
the expression of IL-17. Th1 and Th17 cells in particu-
lar, and their associated cytokines, have been implicated in
the pathogenesis of autoimmune diseases such as multiple
sclerosis (MS) [35–37].
Several genes controlling immune functions are known to
be regulated by DNA methylation, although our under-
standing of the impact of epigenetic modifications in the
regulation of T cell functions is currently still limited. The
fact that DNA methylation can be dynamically modulated
during T cell responses to an antigen is suggested by a
number of observations. For instance, the Il2, Il4 and Ifng
cytokine genes are known to be regulated by DNA methyl-
ation in T cells [38–40]. In the absence of DNMT1 or
DNMT3a (but not DNMT3b), murine CD4+ T lympho-
cytes were unable to silence properly the Ifng and Il4 loci
under appropriate culture conditions, resulting in increased
and promiscuous cytokine expression [41–43]; even T cells
lacking MBD2 (methyl-CpG-binding domain protein 2), a
reader of methylated DNA, showed a similar phenotype
[44]. T cell activation in Th2-polarising conditions was
shown to reduce substantially recruitment of DNMT1 to
the Il4-Il13 locus in proliferating cells, eventually lead-
ing to reduced DNA methylation of this locus and en-
hanced gene expression [39]. Dysregulated Th2-type cy-
tokine expression in the absence of DNMT1 was observed
even in CD8+ T cells, indicating defective gene silencing
[45]. Moreover, DNMT3a expression was shown in the
Figure 2
DNA methylation dynamics regulate cytokine production in T
lymphocytes. DNA methylation modulates cytokine production
upon T cell activation, and active demethylation processes
(independent of cell replication) have been shown to act at some
cytokine loci. Hypothetically, these processes may involve TET
proteins as an underlying mechanism of demethylation.
5hmC = 5-hydroxymethylcytosine; 5mC = 5.methylcytosine; IFNγ =
interferon-gamma; IL = interleukin; TET = ten-eleven translocation
mouse to be increased by T cell receptor (TCR) engage-
ment. Accordingly, Dnmt3a-null murine T cells showed
hypomethylated cytokine loci and dysregulated cytokine
expression [41]. More recently, genome-wide methylation
studies investigated changes in DNA methylation in effect-
or and memory murine T cells compared with their naïve
counterparts, highlighting the extent of chromatin remod-
elling events accompanying the acquisition of the effector/
memory phenotype upon stimulation of a naïve T cell [46,
47].
Prior to the discovery of TET proteins, models for DNA
demethylation placed emphasis on a passive process due
to a failure of DNMT1 to methylate the newly synthesised
DNA strand during the S phase of the cell cycle. However,
the rapid and DNA replication-independent demethylation
of the Il2 locus that was observed upon activation of CD4+
T cells and that causally affected Il2 gene transcription was
inconsistent with such a model [40]. Along the same line,
dynamic methylation of the Ifng locus was described for
memory CD8+ T lymphocytes: while this locus was par-
tially methylated at resting state, it underwent demethyl-
ation within 5 hours of antigenic stimulation [38]. This
process was independent of DNA replication and cell divi-
sion, and the involvement of a yet unidentified demethylase
activity was proposed [38] (fig. 2). Interestingly, character-
isation of the genome-wide distribution of 5hmC in mouse
CD4+ T cells could not lead to a definitive answer about
the role of 5hmC in T cell differentiation, although it
showed a clear effect of TET2 in modulating effector re-
sponses in some T cell subsets, with reduced IL-10, IFNγ
and IL-17A production in the absence of TET2 [48].
Among the various T cell subsets required to regulate im-
mune responses properly, regulatory T cells (Tregs) are es-
sential to suppress fatal autoimmunity throughout the life-
time of an organism. These cells are characterised by the
expression of the transcription factor Foxp3, which plays a
key role in their differentiation and function. Indeed, muta-
tions or deficiency of the Foxp3 gene lead to the develop-
ment of autoimmune disease, causing the scurfy phenotype
in mice and IPEX (immune dysfunction, polyendocrino-
pathy, X-linked) syndrome in humans [49]. Stable Foxp3
expression is essential to maintain Treg cell identity and
functional integrity, and mechanisms are in place to pre-
serve Treg cell lineage stability [50]. In particular, regu-
latory regions in the Foxp3 locus have to be maintained
free of methylation in order to confer phenotypic stability
to Tregs and, accordingly, inhibition of DNA methylation
using 5-azacytidine or 5-aza-deoxycytidine led to stable
Foxp3 expression [49–51]. By modulating the stability of
the Treg phenotype, DNA methylation could therefore also
have an impact on the onset of autoimmune diseases, and
DNMT inhibitors were proposed as potentially useful tools
to enhance Foxp3 expression in an attempt to limit inflam-
mation [49]. Expression of DNMT1, but not DNMT3a,
was, however, shown to be essential for the appropriate dif-
ferentiation and function of Tregs, and mice with condi-
tional deletion of DNMT1 in Tregs died of lethal autoim-
munity [52]. DNA methylation therefore appears to have a
complex role in regulating Treg stability and function that
may hinder the development of epigenetic-based therapies.
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DNA methylation in autoimmune and
autoinflammatory diseases
Although the aetiology of MS and other autoimmune dis-
eases is still largely unknown, it involves T cell-mediated
processes [35]. Genome-wide association studies (GWAS)
on MS patients have identified several genetic loci associ-
ated with a greater risk of developing the disease. Of these,
the most commonly identified risk locus in MS and other
autoimmune diseases is the major histocompatibility com-
plex (MHC), pointing towards a fundamental role for an-
tigen presentation, but many of the other loci associated
with MS risk are related to immune functions, including
cytokines and cytokine receptors, costimulatory receptors
and signal transduction molecules [53].
Epigenetic mechanisms of regulation of gene expression
may partly explain why only a proportion of genetically
susceptible individuals may end up manifesting the disease.
The complexity of such regulation and its impact on dis-
ease is exemplified by investigations on monozygotic
twins: despite sharing identical genetic material, the risk of
developing MS in a twin of an MS patient is only 25%,
although it remains higher than in dizygotic twins or non-
twin siblings [54]. Similarly, besides genetic predisposi-
tion, epigenetic factors appear to be important for the onset
of systemic lupus erythematosus (SLE), since monozygot-
ic twins are often discordant also for this disease [55]. To
assess the relative contribution of heritable vs nonheritable
influences on a variety of immunological parameters, a re-
cent work investigated responses of 210 healthy twin pairs
[56]. Interestingly, immune variation in this system was
dominated by nonheritable determinants, some of which
also became more divergent with age, suggesting a cumu-
lative effect of environmental exposure [56].
Despite the clear evidence of an environmental component
in disease development, it has not been easy to pinpoint
the exact impact of epigenetics in autoimmune diseases;
for example, a study investigating three monozygotic twin
pairs discordant for MS found no reproducible differences
in DNA methylation, single nucleotide polymorphisms or
gene expression in CD4+ T cells [57]. A more recent study
evaluated genetic and epigenetic determinants of 21
autoimmune diseases, observing that most causal variants
map to enhancers rather than protein-coding genes and
frequently coincide with regions bound by transcription
factors and depleted of nucleosomes [58]. On the other
hand, DNA methylation in cells of monozygotic twins dis-
cordant for the disease was also analysed in the case of type
1 diabetes (T1D), and the differentially methylated regions
included several genes involved in immune responses [59].
Interestingly, some of the DNA methylation sites associ-
ated with T1D could be detected years before clinically
overt T1D, suggesting a role in increasing the risk of devel-
oping this disease [59]. Changes in DNA methylation have
been demonstrated also in SLE patients, with T lymph-
ocytes from these patients showing overall genomic hy-
pomethylation compared with controls [55]. Most import-
antly, exposing T cells to demethylating drugs resulted in
the induction of a lupus-like disease in mice [60]. Although
the mechanisms by which hypomethylated T cells induce
SLE are not fully understood, recent evidence points to-
wards a possible dominant role for IL-10 and IL-17 pro-
duction in T cells, dependent on altered methylation status
at these loci [61, 62]. Altered global DNA methylation and
dysregulation at specific genetic loci have also been re-
ported for rheumatoid arthritis (reviewed in [63, 64]), al-
though a comprehensive view of the role of DNA methyla-
tion in autoimmunity and whether in each case it represents
a cause or consequence is still lacking.
DNA methylation in disease: cause, consequence or
correlation?
Aberrant DNA methylation is a pervasive feature of human
tumours, which often show extensive genomic hypo-
methylation together with hypermethylation of tumour-
suppressor genes (reviewed in [65]). As cancer progresses,
the level of global methylation decreases, and DNA hypo-
methylation may contribute to cancer progression through
chromosomal instability, reactivation of transposable ele-
ments and loss of imprinting [65]. Vice versa, hypermethyl-
ation of tumour-suppressor genes can have a major impact
in suppressing the expression of these genes and therefore
unleash uncontrolled cell proliferation. Similarly, global
loss of 5hmC is a hallmark of a number of different tu-
mours [66-68], although in spite of the diagnostic and pro-
gnostic implications, the clear biological significance of
such altered methylation patterns remains to be fully under-
stood. Importantly, alterations in the distribution of histone
modifications have been described for a number of autoim-
mune diseases [63], and given the interplay between post-
translational modification of histones and DNMT enzymes
[69], at least part of the altered DNA methylation patterns
observed in disease may potentially be linked to histone
modifications.
While a causal link between mutations in DNA-modifying
enzymes, altered methylation patterns and disease has been
worked out in some cases [7, 8, 66], it has to be highlighted
that some biological consequences of altered methylation
do not necessarily link directly to disease. Indeed, changes
in DNA methylation and hydroxymethylation are imper-
fectly maintained during replication and are subject to con-
siderable epigenetic drift, that is, gradual increase or de-
crease at specific loci [70]. Such stochastic drift not only
creates epigenetic mosaicism within populations, but it is
also part of the normal process of aging, with aging cells
and tissues showing considerable DNA hyper- or hypo-
methylation over time [70, 71]. Moreover, while some
mouse models lacking DNMT3a or TET2 develop haema-
topoietic malignancies [7, 8, 30, 31, 33], this is not the
case for mice lacking other DNMT or TET family mem-
bers, suggesting that altered methylation patterns do not ne-
cessarily lead straight to disease. They can however pre-
dispose to its onset, and the lack of DNMT3a in particular
appeared to confer flexibility to the methylome of haema-
topoietic stem cells, allowing cellular transformation after
the acquisition of additional mutations [7, 8].
Interestingly, although the underlying mechanism remains
unclear, chronic inflammation can be an important inducer
of epigenetic drift, and potentially predisposing to the onset
of disease. For example, Helicobacter pylori is a well-
known inducer of chronic inflammation and gastric cancer,
and altered patterns of DNA methylation are associated
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with H. pylori infection. In a gerbil model of gastric cancer,
H. pylori infection was sufficient to induce DNA methyla-
tion in gastric epithelial cells, which could be partially re-
versed by H. pylori eradication or blocked by immunosup-
pressive drugs [72], suggesting that inflammation induced
by the infection was a critical determinant of hypermethyl-
ation. Other determinants of methylation variations remain
poorly understood [70].
MicroRNAs, immune regulation and
autoimmunity
MicroRNAs have recently emerged as important regulators
of both transcriptional and epigenetic programmes, with
pivotal roles in regulating early T cell development, lineage
specification and function [73]. As a result of their stability,
miRNAs are most suitable to maintain memory of altered
cellular states [3] and it is becoming increasingly clear that
they are involved in regulating various aspects of autoim-
munity (reviewed in [74, 75]), as well as in the regulation
of DNA-modifying enzymes. For instance, miR-21 and
miR-148a were shown to be highly expressed in patients
with SLE, and to promote hypomethylation by repressing
DNMT1 expression [76]. This in turn led to increased ex-
pression of autoimmune-associated genes like CD70 and
LFA-1, surface markers that were shown to play a role in
lupus [55].
A growing number of studies also identified miRNAs as
potential novel therapeutic targets in animal models of MS
as well as in primary cells derived from MS patients (table
1). For example, miR-155 and miR-29ab expression was
found to be elevated in mouse CD4+ T cells during ex-
perimental autoimmune encephalomyelitis (EAE), and
miR-155– or miR-29ab–deficient mice had a delayed
course and reduced severity of disease [77, 78]. Another
relevant example is provided by miR-326, whose expres-
sion was highly correlated with disease severity in patients
with MS and in mice with EAE. Accordingly, modulation
of miR-326 expression altered disease severity [79]. Vice
versa, miR-20 was shown to be downregulated during
Figure 3
Interplay between miRNAs and the DNA methylation
machineries. MiRNAs are both target and effector of epigenetic
modifications. Expression of miRNAs can be modulated by levels of
DNA methylation in the gene locus of any given miRNA. In turn,
mature miRNAs bind the 3’UTR of target mRNAs leading to a
reduction in protein output. DNMT and TET mRNAs can be
targeted by miRNAs such as miR-29, miR-22 and others, thereby
modulating the levels of DNA methylation and hydroxymethylation.
DNMT = DNA methyltransferase; miRNA = micro RNA; mRNA =
messenger RNA; TET = ten-eleven translocation protein; UTR =
untranslated region
Table 1: Common miRNAs dysregulated in autoimmune diseases. Examples of some common miRNAs that have been reported to influence autoimmunity in general,
MS or its experimental model (EAE) in humans (Hsa), mouse (Mmu) or rat (Rno).
miRNA Expression change Target/ Function Model system Outcome PMID
–
(Dicer/Drosha
deletions)
All miRNAs down Elimination of components of the miRNA
machinery in Tregs
Mmu Fatal autoimmunity 18725525
18725526
18725527
Let-7e Up Dysregulated cytokine production Mmu Silencing ameliorated EAE 23079871
miR-10 Up Bcl-6, T cell plasticity Mmu Delayed onset of EAE 22544395
miR-17~92 Up Treg functions Mmu Treg-specific loss of miR-17~92
results in exacerbated EAE
23858035
20148420
miR-20b Down Disease severity, Th17 responses Mmu Overexpression leads to reduced
severity of EAE
24842756
miR-23b Down Suppresses inflammatory cytokine-mediated
signaling
Hsa/ Mmu Overexpression leads to reduced
severity of EAE
22660635
miR-29 Up in MS and EAE T-bet, IFNg, Th1 differentiation Hsa/ Mmu Knock-out mice have reduced EAE 22772450
miR-132/212 Up Th17 differentiation Mmu Exacerbated EAE 23818645
miR-155 Up Positive regulator of inflammation Mmu Knock-out mice have reduced EAE 20888269
21788439
miR-181 Up Regulates threshold of TCR activation Hsa/ Rno Upregulated in CD4+ T cells of
strains susceptible to EAE and in
cerebrospinal fluid of MS patients
17382377
25775432
23514736
23077021
miR-301 Up Th17 differentiation Mmu Exacerbated EAE 22517757
miR-326 Up Disease severity, Th17 responses Hsa/ Mmu Expression correlates with disease 19838199
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EAE, and its overexpression led to reduced disease severity
in mice [80].
In MS patients, distinct miRNA expression profiles were
found in CD4+ and CD8+ T cells as well as B cells as
compared with healthy donors, and miR-17-5p, another
miRNA known to be involved in autoimmunity, was up-
regulated in CD4+ T cells from MS patients [81]. Further
highlighting the importance of miRNAs in regulating vari-
ous aspects of human disease, a role has even been pro-
posed in the regulation of blood-brain barrier endothelial
tightness in MS patients [82]. Moreover, miRNAs have
been investigated as promising biomarkers for disease, be-
ing able to discriminate MS from other neurological dis-
eases, as well as different disease courses of MS [83].
Despite encouraging results underscoring the role of
miRNAs in autoimmune diseases, the biological function
of most of these miRNAs and their relevance for disease
in the context of MS is mostly unknown. MiR-181a is a
miRNA known to regulate the threshold of TCR activation
in developing thymocytes and to contribute to positive se-
lection in the thymus [84–86]. Interestingly, miR-181a was
found to be elevated upon EAE induction in lymph nodes
of EAE-susceptible Dark Agouti rats as compared with the
EAE-resistant rat strain Piebald Virol Glaxo [87]. Anoth-
er miRNA of the same family, miR-181c, was shown to
be increased in the cerebrospinal fluid of patients with MS
compared with other neurological diseases, and to differ-
entiate relapsing-remitting from secondary progressive MS
courses [83]. MiR-181c‒containing extracellular vesicles
were also shown to trigger the breakdown of the blood-
brain barrier in a model of brain metastatic cancer [88].
Finally, miR-181b was shown to be elevated in CD4+ T
cells from SLE patients, as compared with healthy con-
trols, in a manner that was potentially linked to DNA hy-
pomethylation in these patients [89]. To understand the
biological relevance of this miRNA in regulating the ac-
tivation and function of T cells, and therefore a possible
role in disease onset or progression, our lab investigated
the role of miR-181a in the activation of primary human T
cells upon recognition of specific antigens [90]. We found
that miR-181a expression regulated the threshold of ac-
tivation of primary human T helper cells, especially of
the Th17 type, known to be involved in MS pathogenesis
[35, 37]. Moreover, we showed that, given two memory T
cells bearing the same identical TCR (therefore with the
same antigen recognition capacity), the cell expressing the
highest levels of miR-181a became able to respond with
full-blown activation and overt proliferation to the lowest
concentrations of cognate antigen, regardless of the pheno-
type, strongly suggesting the possibility that miRNAs may
also be important regulators of the threshold of T cell re-
sponses toward autoantigens in autoinflammatory diseases
[90]. More studies in this direction will enable us to under-
stand the specific roles played by these regulatory molec-
ules in the modulation of autoimmune responses.
Interplay between DNA-modifying enzymes and
miRNAs
To fully grasp the level of complexity of the mechanisms
involved in fine-tuning the regulation of gene expression,
one should also consider the interplay between DNA
methylation and miRNA expression. Indeed, miRNAs can
play a role in the modulation of DNA methylation both as
targets (that is, DNA methylation can alter miRNA expres-
sion and consequently expression of downstream genes)
and as effectors (that is, miRNAs reduce the expression of
target DNA-modifying enzymes) (fig. 3).
For instance, the miR-29 family was shown to target
DNMT1, DNMT3a and DNMT3b, leading to global DNA
hypomethylation and re-expression of tumour suppressor
genes in acute myeloid leukaemia cells [91]. Interestingly,
miR-29 family members were also shown to be able to tar-
get TET enzymes, suggesting that this family of miRNAs
acts primarily by protecting cells against perturbations in
the existing DNA methylation landscape [92]. Similarly,
miR-22 was shown to target directly TET proteins and to
contribute to leukaemia development and metastatic poten-
tial of cancer cells [93, 94]. By utilising an unbiased high-
throughput 3’ untranslated region activity screen of 460
miRNA constructs, a recent work showed that TET2 is un-
der extensive regulation by more than 30 miRNAs (includ-
ing miR-29b, miR-29c, miR-101, miR-125b, and miR-7)
able to reduce TET2 expression and levels of genomic 5h-
mC and to disrupt normal haematopoiesis [95].
Looking at the molecular interplay between DNA methyl-
ation and miRNAs in the opposite direction, the list of
miRNA genes that can be silenced by DNA methylation,
especially in cancer, is constantly growing [96], and given
the impact of miRNAs in regulating virtually every single
aspect of T cell biology [73], it would not be surprising to
identify miRNAs whose methylation-dependent silencing
leads to dysregulated immune responses.
An interesting aspect of miRNA-mediated regulation is
also related to the fact that selected miRNAs can be ex-
changed through exosomes during immune synapse form-
ation between T cells and antigen-presenting cells (APCs)
[97]. The flow of exchange was shown to be unidirectional,
from the T cell to the APC, and to be able to influence
gene expression in the recipient cell. Such mechanism of
exchange was also shown to occur between Tregs and vari-
ous immune cell types, and to suppress proliferation and
cytokine secretion by pathogenic Th1 cells [98]. Import-
antly, miRNAs were transferred to Th1 cells both in vitro
and in vivo, and such transfer significantly contributed to
suppression and prevention of systemic inflammation in
mice [98]. Whether exosome-mediated miRNA exchange
is also able to modulate the epigenetic status of the receiv-
ing cell remains to be evaluated, and is an exciting ques-
tion that will undoubtedly be addressed in work to come
(box 1). Intriguingly, RNA molecules can also be methyl-
ated, and methylation of primary miRNAs (pri-miRNAs)
was recently shown to act as a post-transcriptional mark
promoting further miRNA processing [99]. Whether such
‘‘epitranscriptomic’’ modifications [100] will become rel-
evant also in the context of disease will be an exciting topic
for the future.
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Box 1: Future challenges and outstanding questions
- What is the pattern of DNA methylation and hydroxymethylation in
T cells in vivo?
- How does epigenetic variation impact disease? Is there a role for
5hmC in autoimmune diseases?
- What are the mechanisms that dictate the activity of DNA-modify-
ing enzymes at specific genomic loci?
- Are there any DNA methylation-independent functions for DNMT
and TET proteins?
- Are small molecules interfering with 5hmC dynamics going to be
effective and useful in the clinic?
- Are miRNAs able to significantly alter the epigenome in vivo and in
disease?
Diet and metabolism
T cell metabolism
The role of metabolism in regulating T cell differentiation
and function is becoming increasingly clear (reviewed in
[101, 102]). Specifically, naïve, antigen-inexperienced T
cells have a quiescent metabolism and generate energy
primarily through oxidative phosphorylation (OXPHOS).
Upon activation, effector T cells undergo a profound meta-
bolic reprogramming and induce aerobic glycolysis, which
is energetically less efficient, but supplies metabolic in-
termediates for biosynthesis of molecules required to sus-
tain intense proliferation. Finally, memory T cells preferen-
tially engage OXPHOS fuelled by the catabolism of fatty
acids [101]. Metabolic pathways can also bias T helper
cell differentiation towards specific subsets, thereby poten-
tially influencing the outcome of an inflammatory response
or autoimmune pathology [103]. Given the importance of
metabolic pathways in regulating T cell responses, it is not
surprising that pharmacological inhibition of some crucial
metabolic regulators such as AMPK (AMP-activated pro-
tein kinase) have shown some effects in mouse models of
EAE [102]. While the rodent models of EAE are extremely
useful to dissect the mechanisms leading to or exacerbating
disease, confirmation in the human system will be required
to translate such potentially important findings to the clinic.
Dietary habits and epigenetic modifications
There is currently a great deal of interest regarding the pos-
sible link between diet, epigenetic modifications and dis-
ease. Vitamins and trace elements are important cofactors
of a wide variety of enzymes as well as donors of chemical
groups for epigenetic modifications. Folate is an essential
B vitamin whose derivatives are main effectors in methyl-
ation reactions. Specifically, derivatives of folate are cru-
cial to maintain appropriate methionine levels in the cells,
which in turn is utilised to generate S-adenosylmethionine
(SAM), the universal donor of methyl group [104]. Dietary
folate intake is one of the few established links between
diet and epigenetic modifications in both mouse (such as
in the Agouti mouse model) and humans, as shown in rural
Gambian women whose diet changes drastically accord-
ing to the rainy and dry seasons [105, 106]. These studies
showed that maternal folate intake is able to impact the es-
tablishment on 5mC patterns in the offspring.
Vitamin C is an essential nutrient for humans and primates,
which have lost the capacity to synthesise it from glucose.
Vitamin C acts as an antioxidant, able to maintain the
redox state of iron-containing enzymes, and consequently
to maintain the activity of dioxygenases such as TET en-
zymes [107]. As a result, vitamin C treatment of cultured
cells led to a striking increase in the levels of genomic 5h-
mC, strongly influencing gene expression and differenti-
ation potential [108]. However, whether altered levels of
these cofactors can impact directly immune responses re-
mains unclear. Vice versa, among the environmental factors
known to impact the risk of MS are levels of vitamin D,
whose serum levels are inversely correlated with the risk
of MS. Vitamin D also appears to influence the course of
MS, as lower levels are associated with increased severity
of the disease [109]. Despite the fact that dietary habits and
environmental factors can clearly have an influence of epi-
genetic modifications as well as on disease susceptibility,
a precise link between these factors is still somewhat loose
and the magnitude of these effects remains to be fully de-
termined.
Epigenetic “resetting” of
autoimmunity?
Although two major demethylating agents (decitabine and
its analogue azacitidine) are now commonly used in the
clinic for treatment of myelodysplastic syndrome and some
leukaemias, the mechanisms underlying their clinical effic-
acy remain to be fully elucidated [110]. While genetic alter-
ations are permanent, epigenetic modifications are poten-
tially reversible, opening the possibility to utilise epigen-
etic drugs to at least relieve a certain phenotype. One of
the major obstacles in this direction is, however, linked to
the fact that there is still a paucity of information about the
impact on disease of global changes in methylation versus
gene-specific alterations. For example, despite the global
hypomethylation observed in SLE patients, gene-specific
hypermethylation cannot be ruled out. Moreover, the im-
pact of other DNA modifications, such as 5hmC and its fur-
ther products of oxidation, on gene transcription and dis-
ease remains for the most part to be uncovered. In general,
a better understanding of the mechanisms that drive aber-
rant methylation and their pathological importance will be
crucial to be able to exploit them for therapeutic purposes.
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Figures (large format)
Figure 1
DNA methylation and hydroxymethylation. Cytosine modifications in DNA have functional consequences on gene expression. (a) Cytosine
can be methylated by DNMT enzymes to give rise to 5mC, which can be oxidised by TET enzymes to 5hmC and further products (5fC and
5caC). In an active demethylation pathway, these products of TET enzymatic activity are likely to be excised and repaired by the thymine-DNA
glycosylase enzyme and base excision repair mechanisms to regenerate the unmodified cytosine. Methylated DNA can be recognised by MBD
proteins that can recruit histone modifying complexes (HMTs and HDACs). (b) DNA methylation occurs at regulatory regions (such as
promoters), but also in gene bodies. DNMT enzymes are responsible for 5mC deposition, often resulting in the transcriptional repression of the
methylated promoter. TET proteins activity can lead to demethylation with a potential for transcriptional activation.
5caC = 5-carboxylcytosine; 5fC = 5-formylcytosine; 5hmC = 5-hydroxymethylcytosine; 5mC = 5-methylcytosine; BER = base excision repair;
DNMT = DNA methyltransferase; HDAC = histone deacetylase; HMT = histone methyltransferase; MBD = methyl-CpG-binding domain protein;
TDG = thymine-DNA glycosylase; TET = ten-eleven translocation
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Figure 2
DNA methylation dynamics regulate cytokine production in T lymphocytes. DNA methylation modulates cytokine production upon T cell
activation, and active demethylation processes (independent of cell replication) have been shown to act at some cytokine loci. Hypothetically,
these processes may involve TET proteins as an underlying mechanism of demethylation.
5hmC = 5-hydroxymethylcytosine; 5mC = 5.methylcytosine; IFNγ = interferon-gamma; IL = interleukin; TET = ten-eleven translocation
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Figure 3
Interplay between miRNAs and the DNA methylation machineries. MiRNAs are both target and effector of epigenetic modifications.
Expression of miRNAs can be modulated by levels of DNA methylation in the gene locus of any given miRNA. In turn, mature miRNAs bind the
3’UTR of target mRNAs leading to a reduction in protein output. DNMT and TET mRNAs can be targeted by miRNAs such as miR-29, miR-22
and others, thereby modulating the levels of DNA methylation and hydroxymethylation.
DNMT = DNA methyltransferase; miRNA = micro RNA; mRNA = messanger RNA; TET = ten-eleven translocation protein; UTR = untranslated
region
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